Allergen immunotherapy: a practice parameter third update.

@article{Cox2011AllergenIA,
  title={Allergen immunotherapy: a practice parameter third update.},
  author={Linda S. Cox and Harold S. Nelson and Richard F. Lockey and Christopher W. Calabria and Thomas Chacko and Ira Finegold and Michael Nelson and Richard W. Weber and David I Bernstein and Joann Blessing-Moore and David A. Khan and David Michael Lang and Richard A. Nicklas and J. Oppenheimer and Jay M. Portnoy and Christopher C. Randolph and Diane E. Schuller and Sheldon L. Spector and Stephen A. Tilles and Dana Wallace},
  journal={The Journal of allergy and clinical immunology},
  year={2011},
  volume={127 1 Suppl},
  pages={
          S1-55
        }
}
These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American Col- lege of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology. The American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology have jointly accepted responsibility for establishing ''Allergen immunotherapy: A practice parameter third update… 
Atopic dermatitis: a practice parameter update 2012.
TLDR
This parameter was developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI), the American College of All allergy, asthma, and immunology (ACAAI); and the Joint Council of allergy, asthma and Immunology, and is designed for use by pharmaceutical companies in drug promotion.
What’s New With Allergy Shots? Overview of the Joint Task Force’s Third Update on Allergen Immunotherapy
TLDR
This update accesses the latest research to establish guidelines for the safe and effective use of allergen IT practice and aims to ensure the optimal practice ofallergen immunotherapy (IT) for patients with allergic disease.
Practice parameter Atopic dermatitis : A practice parameter update 2012
This parameter was developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma &
Allergen immunotherapy practice in the United States: guidelines, measures, and outcomes.
TLDR
It will likely become more important for US allergy/immunology practices to demonstrate immunotherapy comparative-effectiveness and report quality measures, and evolving trends in how immunotherapy outcomes will be measured and assessed are discussed.
Historical perspectives of allergy and immunology and allergen immunotherapy.
  • R. Lockey
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2014
During my youth, I had my first encounter with the specialty of allergy while assisting my physician-father, an allergist/immunologist, in preparing allergen extracts from ragweed pollen and house
Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report.
TLDR
An expert team was nominated to develop a comprehensive consensus report on the mechanisms of AIT and its use in clinical practice, as well as unmet needs and ongoing developments in AIT.
Allergen immunotherapy practice patterns: a worldwide survey.
  • P. Ponda, S. Mithani, +4 authors V. Bonagura
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2012
TLDR
Given the wide variability in how allergists adjust dose and frequency of immunotherapy during pollen seasons, establishing guidelines regarding this routine dilemma might help standardize the delivery of treatment to patients.
Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence.
TLDR
The role of AIT as a valuable therapeutic strategy for prevention of exacerbation and progressive decline in lung function is highlighted and a summary of recommendations on the more relevant topics are proposed.
A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema.
TLDR
These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology, representing the AAAAI, the ACAAI, and the Joint Council of All allergy, asthma and Immunology.
ALLERGEN IMMUNOTHERAPY: EFFICACY, PERSISTENCE, CONSISTENCY, AND COST EFFECTIVENESS
TLDR
There are discussed following topics of allergen immunotherapy: the reasons for recommending AIT, mechanism of action, subcutaneous and sublingual methods of application, duration, adherence and cost effectiveness.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 597 REFERENCES
Allergen immunotherapy: a practice parameter second update.
  • I. Bernstein
  • Medicine
    The Journal of allergy and clinical immunology
  • 2007
TLDR
This document incorporated the efforts of many participants, and no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters.
The diagnosis and management of anaphylaxis practice parameter: 2010 update.
TLDR
These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology, the ACAAI, and the Joint Council of All allergy, asthma and Immunology and are not designed for use by pharmaceutical companies in drug promotion.
The diagnosis and management of anaphylaxis
TLDR
These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, and are not designed for use by pharmaceutical companies in drug promotion.
Allergen immunotherapy: guidelines, update, and recommendations of the World Health Organization.
TLDR
Interpretation of the history, physical findings, and skin and laboratory tests, the prescription and administration of allergen immunotherapy, its integration into the patient's treatment plan, and the decision to discontinue it require qualifying experience provided by specialist training in allergy and immunology.
Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper.
TLDR
The document summarizes the scientific literature and rationale for the appropriate use of such therapy to treat allergic rhinoconjunctivitis, allergic asthma, and Hymenoptera hypersensitivity, and offers recommendations for areas of additional and necessary research.
American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis.
TLDR
The OJTF report provides recommendations for physicians who prescribe Xolair (omalizumab) on (1) the suggested wait periods after administration and (2) patient education regarding anaphylaxis.
Sublingual immunotherapy: a comprehensive review.
TLDR
Despite clear evidence that SLIT is an effective treatment, many questions remained unanswered, including effective dose, treatment schedules, and overall duration of treatment, and an assessment of the cost/benefit ratio of the treatment cannot be made.
Survey of fatalities from skin testing and immunotherapy 1985-1989.
TLDR
The annual fatality rate from administration of allergenic extracts in the United States remains very low: 1 fatality per 2 million doses, but additional educational efforts to further reduce theFatality rate are needed.
Allergen immunotherapy for asthma.
TLDR
Immunotherapy may reduce asthma symptoms and use of asthma medications, but the size of the benefit compared to other therapies is not known.
Comparison of allergen immunotherapy practice patterns in the United States and Europe.
  • L. Cox, L. Jacobsen
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2009
TLDR
Significant differences and similarities exist in SIT practice patterns of US and European allergy specialists, primarily in the availability of allergen extracts and how these extracts are formulated.
...
1
2
3
4
5
...